Deze pagina is automatisch vertaald en de nauwkeurigheid van de vertaling kan niet worden gegarandeerd. Raadpleeg de Engelse versie voor een brontekst.

Zwangerschapsbewaking op afstand om de toegang te verbeteren (REACTIVE)

19 oktober 2026 bijgewerkt door: Samuel Parry, MD, University of Pennsylvania

Zwangerschapsmonitoring op afstand om de toegang te verbeteren: de REACTIVE Trial

The goal of this clinical trial is to determine the effectiveness of remote nonstress test (NST) compared to in-clinic NSTs in improving fetal testing completion rates. Participants will be randomized to either in-clinic NSTs or use of an FDA-approved remote monitoring belt for their pregnancy monitoring.

Studie Overzicht

Toestand

Voltooid

Conditie

Studietype

Ingrijpend

Inschrijving (Werkelijk)

400

Fase

  • Niet toepasbaar

Contacten en locaties

In dit gedeelte vindt u de contactgegevens van degenen die het onderzoek uitvoeren en informatie over waar dit onderzoek wordt uitgevoerd.

Studie Locaties

    • Pennsylvania
      • Philadelphia, Pennsylvania, Verenigde Staten, 19104
        • University of Pennsylvania

Deelname Criteria

Onderzoekers zoeken naar mensen die aan een bepaalde beschrijving voldoen, de zogenaamde geschiktheidscriteria. Enkele voorbeelden van deze criteria zijn iemands algemene gezondheidstoestand of eerdere behandelingen.

Geschiktheidscriteria

Leeftijden die in aanmerking komen voor studie

  • Kind
  • Volwassen
  • Oudere volwassene

Accepteert gezonde vrijwilligers

Nee

Geslachten die in aanmerking komen voor studie

Vrouw

Beschrijving

Inclusion Criteria:

  • Singleton pregnancy
  • Gestational age between 30 weeks 0 days and 35 weeks 6 days
  • Pregnant patients who have clinical indication for fetal surveillance with NSTs (based on UPHS Health System clinical guidelines for antenatal monitoring)
  • Able to provide written consent
  • English speaking

Exclusion Criteria:

  • Multiple gestations
  • Maternal pre-gravid BMI greater than 45kg/m2
  • Presence of an implanted pacemaker or defibrillator
  • Active abdominal skin infection
  • A known amniotic fluid index (AFI) less than 5cm or greater than 25cm on the most recent ultrasound (if available) prior to randomization
  • Delivery is planned within 2 weeks of potential randomization

Studie plan

Dit gedeelte bevat details van het studieplan, inclusief hoe de studie is opgezet en wat de studie meet.

Hoe is de studie opgezet?

Ontwerpdetails

  • Primair doel: Diagnostisch
  • Toewijzing: Gerandomiseerd
  • Interventioneel model: Parallelle opdracht
  • Masker: Geen (open label)

Wapens en interventies

Deelnemersgroep / Arm
Interventie / Behandeling
Experimenteel: NST op afstand

INVU monitoring belt used for remote NSTs

Actieve vergelijker: NST in de kliniek - zorgstandaard

In-clinic NSTs - standard of care

Wat meet het onderzoek?

Primaire uitkomstmaten

Uitkomstmaat
Maatregel Beschrijving
Tijdsspanne
Fetal Testing Completion Rate
Tijdsspanne: from 32 weeks gestational age to delivery, average of 10 weeks after enrollment.

Percentage of recommended antenatal testing sessions successfully completed, defined as a clinically interpreted test performed. Calculated for each participant as: number of NST visits completed divided by number of NST visits expected × 100.

from 32 weeks gestational age to delivery, average of 10 weeks after enrollment.
Fetal Testing Completion Rate in Black Versus Non-Black Subjects
Tijdsspanne: from 32 weeks gestational age to delivery, average of 10 weeks after enrollment.

Comparison between Black and non-Black subjects' percentage of recommended antenatal testing sessions that were successfully completed as defined as a clinically interpreted test was performed. Calculated as the number of NST visits completed divided by the number of NST visits expected per participant × 100.

from 32 weeks gestational age to delivery, average of 10 weeks after enrollment.

Secundaire uitkomstmaten

Uitkomstmaat
Maatregel Beschrijving
Tijdsspanne
Fetal Monitoring Outcomes: Number of Visits to the Antenatal Testing Unit
Tijdsspanne: from 32 weeks gestational age to delivery, average of 10 weeks after enrollment.

Count of visits to the office for in-person monitoring

from 32 weeks gestational age to delivery, average of 10 weeks after enrollment.
Fetal Monitoring Outcomes: Percentage of Non-Stress Test Sessions Requiring Provider-Recommended Prolonged Monitoring
Tijdsspanne: From randomization until delivery.

For each participant, the percentage of all NST sessions requiring prolonged monitoring (>40 minutes) was calculated. The median participant-level percentage is reported.

From randomization until delivery.
Fetal Monitoring Outcomes: Average Duration of Non-Stress Test Monitoring Sessions
Tijdsspanne: From randomization until delivery.

Mean duration of NST monitoring sessions across all NSTs completed by each participant from randomization to delivery. Participant-level means were calculated and summarized by study arm.

From randomization until delivery.
Fetal Monitoring Outcomes: Non-reactive NST Rate
Tijdsspanne: From randomization until delivery

Percentage of NSTs that were non-reactive among all NSTs completed for each participant.

From randomization until delivery
Fetal Monitoring Outcomes: Percentage of NSTs Resulting in Biophysical Profile Evaluation
Tijdsspanne: From randomization until delivery.

Percentage of completed NSTs followed by biophysical profile assessment.

From randomization until delivery.
Fetal Monitoring Outcomes: Number of Participants With ≥1 Obstetrical Triage Visit
Tijdsspanne: From randomization to delivery

Number of Participants With ≥1 Obstetrical Triage Visit

From randomization to delivery
Fetal Monitoring Outcomes: Number of Participants Who Had Any Triage Visit Directly Related to a Fetal Monitoring Visit
Tijdsspanne: From randomization to delivery

Number of participants who underwent at least one obstetrical triage evaluation directly related to a fetal monitoring visit, during the study period from randomization until delivery.

From randomization to delivery
Fetal Monitoring Outcomes: Number of Participants Recommended for Delivery Based on Findings on Fetal Monitoring Result
Tijdsspanne: From randomization to delivery

Count of the number of subjects in each arm who receive a recommendation for delivery based on the findings of the fetal monitoring results.

From randomization to delivery
Fetal Monitoring Outcomes: Percentage of NSTs Not Completed Within the Prescribed Window
Tijdsspanne: from 32 weeks gestational age to delivery, average of 10 weeks after enrollment.

Percentage of NSTs which occur outside of prescribed window, for example, if a weekly testing regimen is prescribed, an appointment 8 or more days following the last one would count as 1 missed calendar window.

from 32 weeks gestational age to delivery, average of 10 weeks after enrollment.
Obstetrics Outcomes: Gestational Age at Delivery
Tijdsspanne: time of delivery

gestational age at time of delivery

time of delivery
Obstetrics Outcomes: Number of Participants With Preterm Delivery
Tijdsspanne: time of delivery

preterm delivery is defined as less than 37 weeks gestational age

time of delivery
Obstetrics Outcomes: Mode of Delivery
Tijdsspanne: time of delivery

categorized as vaginal or cesarean

time of delivery
Obstetrics Outcomes: Number of Participants With an Indication for Labor Induction
Tijdsspanne: time of labor induction

in subjects who have labor induction, indication for inducing labor

time of labor induction
Obstetrics Outcomes: Number of Participants With an Indication for Cesarean Section
Tijdsspanne: time of delivery

in subjects who have a cesarean section delivery, indication for cesarean section

time of delivery
Obstetrics Outcomes: Number of Participants With Composite Neonatal Morbidity
Tijdsspanne: from delivery to 6 weeks post-delivery

Number of participants whose neonate experienced at least one component of the composite neonatal morbidity outcome, defined as severe respiratory distress, neonatal resuscitation outside the delivery room, or neonatal death.

from delivery to 6 weeks post-delivery
Obstetrics Outcomes: Neonatal Cord Blood pH
Tijdsspanne: time of delivery
time of delivery
Obstetrics Outcomes: Apgar Scores
Tijdsspanne: one and five minutes after delivery

Apgar score at 1 and 5 minutes after delivery. Scores range from 0 to 10, with higher scores indicating better neonatal condition

one and five minutes after delivery
Obstetrics Outcomes: Number of Participants With an Admission to the Neonatal Intensive Care Unit
Tijdsspanne: from delivery to 6 weeks post-delivery
from delivery to 6 weeks post-delivery
Obstetrics Outcomes: Number of Participants Who Had an Admission to the Neonatal Intensive Care Unit for Greater Than 48 Hours
Tijdsspanne: from delivery to 6 weeks post-delivery
from delivery to 6 weeks post-delivery
Obstetrics Outcomes: Maternal Length of Hospital Stay
Tijdsspanne: Delivery hospitalization

Length of maternal hospitalization associated with the delivery admission, measured from hospital admission for delivery through maternal discharge.

Delivery hospitalization
Obstetrics Outcomes: Neonatal Length of Hospital Stay
Tijdsspanne: Birth hospitalization

Length of neonatal hospitalization from birth through hospital discharge.

Birth hospitalization
Cost-effectiveness Outcomes: Productivity Loss Due to Antenatal Testing and Monitoring
Tijdsspanne: From randomization until delivery (approximately 10 weeks on average)

Productivity loss was assessed by summing the number of days of work missed reported by participants across the two study productivity assessments. The reported value represents the total number of work days missed during the study period for each participant.

From randomization until delivery (approximately 10 weeks on average)
Cost-effectiveness Outcomes: Total Societal Perspective Cost
Tijdsspanne: Randomization through delivery

Total societal perspective cost per participant, calculated as the sum of direct healthcare costs, informal healthcare costs, and productivity costs incurred from randomization through delivery. Costs are reported in U.S. dollars (USD). The societal perspective includes costs related to antenatal testing, delivery hospitalization, neonatal care, triage visits, antepartum admissions, productivity losses, caregiving, and transportation.

Randomization through delivery
Implementation Outcomes: Theory-informed Acceptability Questionnaire
Tijdsspanne: at time of delivery

Participant acceptability of the assigned fetal monitoring strategy was assessed using an 8-item Theory-Informed Acceptability Questionnaire (TFA). Total scores range from 8 to 40, with higher scores indicating greater acceptability of the monitoring approach.

at time of delivery

Medewerkers en onderzoekers

Hier vindt u mensen en organisaties die betrokken zijn bij dit onderzoek.

Studie record data

Deze datums volgen de voortgang van het onderzoeksdossier en de samenvatting van de ingediende resultaten bij ClinicalTrials.gov. Studieverslagen en gerapporteerde resultaten worden beoordeeld door de National Library of Medicine (NLM) om er zeker van te zijn dat ze voldoen aan specifieke kwaliteitscontrolenormen voordat ze op de openbare website worden geplaatst.

Bestudeer belangrijke data

Studie start (Werkelijk)

25 mei 2023

Primaire voltooiing (Werkelijk)

26 september 2025

Studie voltooiing (Werkelijk)

26 september 2025

Studieregistratiedata

Eerst ingediend

27 april 2023

Eerst ingediend dat voldeed aan de QC-criteria

27 april 2023

Eerst geplaatst (Werkelijk)

8 mei 2023

Updates van studierecords

Laatste update geplaatst (Werkelijk)

12 november 2026

Laatste update ingediend die voldeed aan QC-criteria

19 oktober 2026

Laatst geverifieerd

1 oktober 2026

Meer informatie

Termen gerelateerd aan deze studie

Informatie over medicijnen en apparaten, studiedocumenten

Bestudeert een door de Amerikaanse FDA gereguleerd geneesmiddel

Nee

Bestudeert een door de Amerikaanse FDA gereguleerd apparaatproduct

Ja

product vervaardigd in en geëxporteerd uit de V.S.

Nee

Deze informatie is zonder wijzigingen rechtstreeks van de website clinicaltrials.gov gehaald. Als u verzoeken heeft om uw onderzoeksgegevens te wijzigen, te verwijderen of bij te werken, neem dan contact op met register@clinicaltrials.gov. Zodra er een wijziging wordt doorgevoerd op clinicaltrials.gov, wordt deze ook automatisch bijgewerkt op onze website .

Abonneren